Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Jumping Today

By George Budwell – Apr 8, 2020 at 11:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its coronavirus program is moving along at warp speed.

What happened

The stock of Novavax (NVAX -3.32%), a small-cap vaccine developer, is on the move today. The biotech's shares are up by 12.9% on heavy volume as of 9:55 a.m. EDT Wednesday morning.

The spark? Novavax's shares are jumping in response to the company's latest update on its coronavirus vaccine program. Ahead of the opening bell, the company announced that it has selected a candidate, dubbed NVX-CoV2373, for clinical trials. A phase 1 trial is expected to get underway by mid-May, with preliminary data slated for this July. 

Up close image of a coronavirus.

Image source: Getty Images.

So what

Novavax's coronavirus program is well ahead of schedule, which is great news for the billions of people at risk of catching this deadly respiratory ailment, and for shareholders. Novavax would only need to capture a small slice of this massive market for this vaccine candidate to be a major value driver for the company. Underscoring this point, the company's market cap is still only $855 million, even after today's double-digit move higher.  

Now what

The bad news is that Novavax probably doesn't have the financial capacity to conduct trials for this vaccine all by itself. Moreover, the company's main focus will surely be the approval and subsequent launch of NanoFlu. That process alone will likely take upward of $100 million. Therefore, no one should get overly excited about the quick pace of this biotech's coronavirus vaccine program, at least not until more grant money becomes available or a partner enters the picture.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$18.08 (-3.32%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.